Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 224

1.

The marrow stem cell niche in normal and malignant hematopoiesis.

Kaushansky K, Zhan H.

Ann N Y Acad Sci. 2019 Feb 14. doi: 10.1111/nyas.14028. [Epub ahead of print] Review.

PMID:
30767234
2.
3.

Hunting for hematopoietic transcriptional networks.

Kaushansky K.

Proc Natl Acad Sci U S A. 2018 Oct 2;115(40):9818-9820. doi: 10.1073/pnas.1813863115. Epub 2018 Sep 10. No abstract available.

4.

JAK2V617F Megakaryocytes Promote Hematopoietic Stem/Progenitor Cell Expansion in Mice Through Thrombopoietin/MPL Signaling.

Zhang Y, Lin CHS, Kaushansky K, Zhan H.

Stem Cells. 2018 Nov;36(11):1676-1684. doi: 10.1002/stem.2888. Epub 2018 Jul 29.

PMID:
30005133
5.

The regulation of normal and neoplastic hematopoiesis is dependent on microenvironmental cells.

Kaushansky K, Zhan H.

Adv Biol Regul. 2018 Aug;69:11-15. doi: 10.1016/j.jbior.2018.06.003. Epub 2018 Jun 27. Review.

PMID:
29970351
6.

JAK2V617F-bearing vascular niche enhances malignant hematopoietic regeneration following radiation injury.

Lin CHS, Zhang Y, Kaushansky K, Zhan H.

Haematologica. 2018 Jul;103(7):1160-1168. doi: 10.3324/haematol.2017.185736. Epub 2018 Mar 22.

7.

The JAK2V617F-bearing vascular niche promotes clonal expansion in myeloproliferative neoplasms.

Zhan H, Lin CHS, Segal Y, Kaushansky K.

Leukemia. 2018 Feb;32(2):462-469. doi: 10.1038/leu.2017.233. Epub 2017 Jul 24.

8.

JAK2V617F-mutant vascular niche contributes to JAK2V617F clonal expansion in myeloproliferative neoplasms.

Lin CH, Kaushansky K, Zhan H.

Blood Cells Mol Dis. 2016 Nov;62:42-48. doi: 10.1016/j.bcmd.2016.09.004. Epub 2016 Nov 4.

9.

Thrombopoietin and its receptor in normal and neoplastic hematopoiesis.

Kaushansky K.

Thromb J. 2016 Oct 4;14(Suppl 1):40. eCollection 2016.

10.

Blood's 70th anniversary: the elusive von Willebrand factor-cleaving protease.

Kaushansky K.

Blood. 2016 May 5;127(18):2163-4. doi: 10.1182/blood-2015-09-636779. No abstract available.

11.

JAK2V617F-mutant megakaryocytes contribute to hematopoietic stem/progenitor cell expansion in a model of murine myeloproliferation.

Zhan H, Ma Y, Lin CH, Kaushansky K.

Leukemia. 2016 Dec;30(12):2332-2341. doi: 10.1038/leu.2016.114. Epub 2016 May 2.

12.

Tribute to Donald Metcalf.

Murphy A, Murphy MJ, Begley CG, Stanley ER, Migliaccio AR, Kaushansky K, Ng AP, Alexander WS, Hilton DJ, Nicola NA.

Stem Cells. 2015 Dec;33(12):3397-421. doi: 10.1002/stem.2237.

13.

Evolving insights into the synergy between erythropoietin and thrombopoietin and the bipotent erythroid/megakaryocytic progenitor cell.

Papayannopoulou T, Kaushansky K.

Exp Hematol. 2016 Aug;44(8):664-8. doi: 10.1016/j.exphem.2015.11.010. Epub 2016 Jan 8. Review.

14.

In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs.

Tefferi A, Kantarjian H, Rajkumar SV, Baker LH, Abkowitz JL, Adamson JW, Advani RH, Allison J, Antman KH, Bast RC Jr, Bennett JM, Benz EJ Jr, Berliner N, Bertino J, Bhatia R, Bhatia S, Bhojwani D, Blanke CD, Bloomfield CD, Bosserman L, Broxmeyer HE, Byrd JC, Cabanillas F, Canellos GP, Chabner BA, Chanan-Khan A, Cheson B, Clarkson B, Cohn SL, Colon-Otero G, Cortes J, Coutre S, Cristofanilli M, Curran WJ Jr, Daley GQ, DeAngelo DJ, Deeg HJ, Einhorn LH, Erba HP, Esteva FJ, Estey E, Fidler IJ, Foran J, Forman S, Freireich E, Fuchs C, George JN, Gertz MA, Giralt S, Golomb H, Greenberg P, Gutterman J, Handin RI, Hellman S, Hoff PM, Hoffman R, Hong WK, Horowitz M, Hortobagyi GN, Hudis C, Issa JP, Johnson BE, Kantoff PW, Kaushansky K, Khayat D, Khuri FR, Kipps TJ, Kripke M, Kyle RA, Larson RA, Lawrence TS, Levine R, Link MP, Lippman SM, Lonial S, Lyman GH, Markman M, Mendelsohn J, Meropol NJ, Messinger Y, Mulvey TM, O'Brien S, Perez-Soler R, Pollock R, Prchal J, Press O, Radich J, Rai K, Rosenberg SA, Rowe JM, Rugo H, Runowicz CD, Sandmaier BM, Saven A, Schafer AI, Schiffer C, Sekeres MA, Silver RT, Siu LL, Steensma DP, Stewart FM, Stock W, Stone R, Storb R, Strong LC, Tallman MS, Thompson M, Ueno NT, Van Etten RA, Vose JM, Wiernik PH, Winer EP, Younes A, Zelenetz AD, LeMaistre CA.

Mayo Clin Proc. 2015 Aug;90(8):996-1000. doi: 10.1016/j.mayocp.2015.06.001. Epub 2015 Jul 23. No abstract available.

15.

Thrombopoiesis.

Kaushansky K.

Semin Hematol. 2015 Jan;52(1):4-11. doi: 10.1053/j.seminhematol.2014.10.003. Epub 2014 Oct 31. Review.

PMID:
25578413
16.

Systems biology of megakaryocytes.

Kaushansky A, Kaushansky K.

Adv Exp Med Biol. 2014;844:59-84. doi: 10.1007/978-1-4939-2095-2_4. Review.

PMID:
25480637
17.

The thrombopoietin receptor, MPL, is critical for development of a JAK2V617F-induced myeloproliferative neoplasm.

Sangkhae V, Etheridge SL, Kaushansky K, Hitchcock IS.

Blood. 2014 Dec 18;124(26):3956-63. doi: 10.1182/blood-2014-07-587238. Epub 2014 Oct 22.

18.

Obesity-driven disruption of haematopoiesis and the bone marrow niche.

Adler BJ, Kaushansky K, Rubin CT.

Nat Rev Endocrinol. 2014 Dec;10(12):737-48. doi: 10.1038/nrendo.2014.169. Epub 2014 Oct 14. Review.

PMID:
25311396
19.

The imperative to invest in science has never been greater.

Carethers JM, Coughlin S, Diamond B, Erzurum S, Fried LP, Jameson JL, Kaushansky K, Klotman ME, Lemon S, Mitchell B, Rothman P, Sawyers C, Seidman C, Somlo S.

J Clin Invest. 2014 Sep;124(9):3680-1. doi: 10.1172/JCI77894. Epub 2014 Sep 2. No abstract available.

20.

Phosphorylated c-Mpl tyrosine 591 regulates thrombopoietin-induced signaling.

Sangkhae V, Saur SJ, Kaushansky A, Kaushansky K, Hitchcock IS.

Exp Hematol. 2014 Jun;42(6):477-86.e4. doi: 10.1016/j.exphem.2014.02.007. Epub 2014 Mar 4.

21.

Thrombopoietin from beginning to end.

Hitchcock IS, Kaushansky K.

Br J Haematol. 2014 Apr;165(2):259-68. doi: 10.1111/bjh.12772. Epub 2014 Feb 6. Review.

PMID:
24499199
22.

JAK2V617F-positive endothelial cells contribute to clotting abnormalities in myeloproliferative neoplasms.

Etheridge SL, Roh ME, Cosgrove ME, Sangkhae V, Fox NE, Chen J, López JA, Kaushansky K, Hitchcock IS.

Proc Natl Acad Sci U S A. 2014 Feb 11;111(6):2295-300. doi: 10.1073/pnas.1312148111. Epub 2014 Jan 27.

23.

Fine-tuning p53 activity through C-terminal modification significantly contributes to HSC homeostasis and mouse radiosensitivity.

Wang YV, Leblanc M, Fox N, Mao JH, Tinkum KL, Krummel K, Engle D, Piwnica-Worms D, Piwnica-Worms H, Balmain A, Kaushansky K, Wahl GM.

Genes Dev. 2011 Jul 1;25(13):1426-38. doi: 10.1101/gad.2024411.

24.

Tensin2 is a novel mediator in thrombopoietin (TPO)-induced cellular proliferation by promoting Akt signaling.

Jung AS, Kaushansky A, Macbeath G, Kaushansky K.

Cell Cycle. 2011 Jun 1;10(11):1838-44. Epub 2011 Jun 1.

25.

Determinants of platelet number and regulation of thrombopoiesis.

Kaushansky K.

Hematology Am Soc Hematol Educ Program. 2009:147-52. doi: 10.1182/asheducation-2009.1.147. Review.

PMID:
20008193
26.

Thrombopoietin in normal and neoplastic stem cell development.

Kaushansky K, Ranney HM.

Best Pract Res Clin Haematol. 2009 Dec;22(4):495-9. doi: 10.1016/j.beha.2009.08.004. Review.

27.

Ubiquitination and degradation of the thrombopoietin receptor c-Mpl.

Saur SJ, Sangkhae V, Geddis AE, Kaushansky K, Hitchcock IS.

Blood. 2010 Feb 11;115(6):1254-63. doi: 10.1182/blood-2009-06-227033. Epub 2009 Oct 30.

28.

Molecular mechanisms of thrombopoietin signaling.

Kaushansky K.

J Thromb Haemost. 2009 Jul;7 Suppl 1:235-8. doi: 10.1111/j.1538-7836.2009.03419.x. Review.

29.

Thrombopoietin regulates c-Myb expression by modulating micro RNA 150 expression.

Barroga CF, Pham H, Kaushansky K.

Exp Hematol. 2008 Dec;36(12):1585-92. doi: 10.1016/j.exphem.2008.07.001. Epub 2008 Sep 23.

30.

Inhibition of GSK-3beta promotes survival and proliferation of megakaryocytic cells through a beta-catenin-independent pathway.

Soda M, Willert K, Kaushansky K, Geddis AE.

Cell Signal. 2008 Dec;20(12):2317-23. doi: 10.1016/j.cellsig.2008.09.001. Epub 2008 Sep 6.

31.

YRRL motifs in the cytoplasmic domain of the thrombopoietin receptor regulate receptor internalization and degradation.

Hitchcock IS, Chen MM, King JR, Kaushansky K.

Blood. 2008 Sep 15;112(6):2222-31. doi: 10.1182/blood-2008-01-134049. Epub 2008 May 16.

32.

Thrombopoietin (TPO) regulates HIF-1alpha levels through generation of mitochondrial reactive oxygen species.

Yoshida K, Kirito K, Yongzhen H, Ozawa K, Kaushansky K, Komatsu N.

Int J Hematol. 2008 Jul;88(1):43-51. doi: 10.1007/s12185-008-0091-6. Epub 2008 May 14.

PMID:
18473128
33.

Cell expansion and maintenance of stemness.

Kaushansky K.

Blood. 2008 Apr 15;111(8):3920-1.

34.

Transcriptional regulation of bone marrow thrombopoietin by platelet proteins.

McIntosh B, Kaushansky K.

Exp Hematol. 2008 Jul;36(7):799-806. doi: 10.1016/j.exphem.2008.02.012. Epub 2008 Apr 14.

35.

Selective inhibition of JAK2-driven erythroid differentiation of polycythemia vera progenitors.

Geron I, Abrahamsson AE, Barroga CF, Kavalerchik E, Gotlib J, Hood JD, Durocher J, Mak CC, Noronha G, Soll RM, Tefferi A, Kaushansky K, Jamieson CH.

Cancer Cell. 2008 Apr;13(4):321-30. doi: 10.1016/j.ccr.2008.02.017.

36.
37.

Historical review: megakaryopoiesis and thrombopoiesis.

Kaushansky K.

Blood. 2008 Feb 1;111(3):981-6. doi: 10.1182/blood-2007-05-088500. Review.

38.

A novel RUNX1 mutation in familial platelet disorder with propensity to develop myeloid malignancies.

Kirito K, Sakoe K, Shinoda D, Takiyama Y, Kaushansky K, Komatsu N.

Haematologica. 2008 Jan;93(1):155-6. doi: 10.3324/haematol.12050.

39.

The American Society of Hematology: a success at age 50.

Jaffé ER, Kaushansky K.

Blood. 2008 Jan 1;111(1):11-5.

40.

Roles of focal adhesion kinase (FAK) in megakaryopoiesis and platelet function: studies using a megakaryocyte lineage specific FAK knockout.

Hitchcock IS, Fox NE, Prévost N, Sear K, Shattil SJ, Kaushansky K.

Blood. 2008 Jan 15;111(2):596-604. Epub 2007 Oct 9.

41.

Immunology. The root of platelet production.

Geddis AE, Kaushansky K.

Science. 2007 Sep 21;317(5845):1689-91. No abstract available.

PMID:
17885117
42.
43.
44.

Endomitotic megakaryocytes that form a bipolar spindle exhibit cleavage furrow ingression followed by furrow regression.

Geddis AE, Fox NE, Tkachenko E, Kaushansky K.

Cell Cycle. 2007 Feb 15;6(4):455-60. Epub 2007 Feb 8.

PMID:
17312391
45.

Hematopoietic growth factors, signaling and the chronic myeloproliferative disorders.

Kaushansky K.

Cytokine Growth Factor Rev. 2006 Dec;17(6):423-30. Epub 2006 Oct 20. Review.

46.

Bloodlines: the importance of mentoring for the future of hematology.

Kaushansky K, Shattil SJ.

Blood. 2007 Feb 15;109(4):1353-4. Epub 2006 Oct 17. No abstract available.

47.

Lineage-specific hematopoietic growth factors.

Kaushansky K.

N Engl J Med. 2006 May 11;354(19):2034-45. Review. No abstract available.

PMID:
16687716
48.

Cytoprotective doses of erythropoietin or carbamylated erythropoietin have markedly different procoagulant and vasoactive activities.

Coleman TR, Westenfelder C, Tögel FE, Yang Y, Hu Z, Swenson L, Leuvenink HG, Ploeg RJ, d'Uscio LV, Katusic ZS, Ghezzi P, Zanetti A, Kaushansky K, Fox NE, Cerami A, Brines M.

Proc Natl Acad Sci U S A. 2006 Apr 11;103(15):5965-70. Epub 2006 Apr 3.

49.

Transcriptional regulation of megakaryopoiesis: thrombopoietin signaling and nuclear factors.

Kirito K, Kaushansky K.

Curr Opin Hematol. 2006 May;13(3):151-6. Review.

PMID:
16567958
50.

Endomitotic megakaryocytes form a midzone in anaphase but have a deficiency in cleavage furrow formation.

Geddis AE, Kaushansky K.

Cell Cycle. 2006 Mar;5(5):538-45. Epub 2006 Mar 1.

PMID:
16552179

Supplemental Content

Loading ...
Support Center